Dianthus Therapeutics

formerly DianthusIPO

Developing Next-Generation Therapies For Severe Autoimmune Diseases

Public · New York, United States · Founded 2021 · $400.0M raised

Headquarters
New York, New York
Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$400.0M
Last Round
$288.0M Venture RoundSep 2023
Rounds
3
Type
Public

About

Dianthus Therapeutics is a clinical-stage biotechnology company developing next-generation complement-targeted antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, claseprubart (DNTH103), is engineered with extended half-life and high selectivity for active C1s complement protein, enabling self-administered subcutaneous injections. A second candidate, DNTH212, is a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation.

Summary

Dianthus Therapeutics is a Biotech company based in New York, United States, founded in 2021. It has raised $400.0M in total across 3 rounds, most recently a $288.0M Venture Round round in Sep 2023. Investors include 5AM Ventures, Bain Capital Life Sciences and Avidity Partners.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundSep 2023
$288.0M

Sign up to see all 3 rounds

Seed through Venture Round — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Dianthus Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/dianthus-therapeutics"><img src="https://indexed.vc/api/badge/company/dianthus-therapeutics" alt="Dianthus Therapeutics on Indexed.vc" width="260" height="76" /></a>